Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Accumulated Expenses (2016 - 2025)

Sonoma Pharmaceuticals has reported Accumulated Expenses over the past 13 years, most recently at $1.7 million for Q1 2025.

  • For Q1 2025, Accumulated Expenses rose 22.41% year-over-year to $1.7 million; the TTM value through Mar 2025 reached $1.7 million, up 22.41%, while the annual FY2025 figure was $1.7 million, 22.41% up from the prior year.
  • Accumulated Expenses for Q1 2025 was $1.7 million at Sonoma Pharmaceuticals, up from $1.4 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $1.7 million in Q1 2025 and troughed at $787000.0 in Q1 2021.
  • A 5-year average of $1.3 million and a median of $1.4 million in 2024 define the central range for Accumulated Expenses.
  • Biggest five-year swings in Accumulated Expenses: dropped 26.99% in 2021 and later surged 38.15% in 2023.
  • Year by year, Accumulated Expenses stood at $787000.0 in 2021, then skyrocketed by 34.56% to $1.1 million in 2022, then surged by 38.15% to $1.5 million in 2023, then dropped by 3.01% to $1.4 million in 2024, then increased by 22.41% to $1.7 million in 2025.
  • Business Quant data shows Accumulated Expenses for SNOA at $1.7 million in Q1 2025, $1.4 million in Q1 2024, and $1.5 million in Q1 2023.